$-0.04 EPS Expected for IntelliPharmaCeutics International Inc. (IPCI)

September 16, 2018 - By Vivian Park

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Logo

Analysts expect IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) to report $-0.04 EPS on October, 9.They anticipate $0.04 EPS change or 50.00 % from last quarter’s $-0.08 EPS. After having $-0.07 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -42.86 % EPS growth. The stock decreased 16.05% or $0.56 during the last trading session, reaching $2.93. About 150,106 shares traded or 698.18% up from the average. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has declined 64.85% since September 16, 2017 and is downtrending. It has underperformed by 80.47% the S&P500.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering IntelliPharmaCeutics International (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. IntelliPharmaCeutics International had 2 analyst reports since May 29, 2018 according to SRatingsIntel. As per Tuesday, May 29, the company rating was maintained by H.C. Wainwright.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $128.37 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

Another recent and important IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news was published by Benzinga.com which published an article titled: “The Daily Biotech Pulse: Immunomedics’ Bottom-Line Miss; Kala, Regeneron Await FDA Verdict” on August 24, 2018.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>